ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  van Rijt, Willem G ^a   Nieuwenhuijs Moeke, Gertrude J ^a   van Goor, Harry ^a   Jespersen, Bente ^b   Ottens, Petra J ^a   Ploeg, Rutger J ^a,c   Leuvenink, Henri G D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ARA290; Erythropoietin; Ischemia reperfusion injury; Kidney transplantation; Pyroglutamate helix B surface peptide

Indexed keywords

ARA 290; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL PIG; FEMALE; GLOMERULUS FILTRATION RATE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY ISCHEMIA; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY;

ANIMALS; DNA PRIMERS; FEMALE; GLOMERULAR FILTRATION RATE; KIDNEY; KIDNEY TRANSPLANTATION; NITRIC OXIDE SYNTHASE; OLIGOPEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE;

EID: 84872038660     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-9     Document Type: Article

References (23)

1. Cohen B, Persijn G, De Meester J. Annual report 1996, Leiden: Eurotransplant international foundation.
2. Oosterlee A, Rahmel A. Annual report 2011, Leiden: Eurotransplant international foundation.
3. Snoeijs MG, Winkens B, Heemskerk MB, et al. Kidney transplantation from donors after cardiac death: a 25-year experience. Transplantation 2010, 90(10):1106-1112. 10.1097/TP.0b013e3181f83b0b, 20861804.
4. Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int 2007, 99(1):162-165. 10.1111/j.1464-410X.2006.06505.x, 16956351.
5. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006, 69(10):1806-1813. 10.1038/sj.ki.5000356, 16598197.
6. Hu L, Yang C, Zhao T, et al. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012, 176(1):260-266. 10.1016/j.jss.2011.06.035, 21816412.
7. Su KH, Shyue SK, Kou YR, et al. Beta common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011, 226(12):3330-3339. 10.1002/jcp.22678, 21321940.
8. Oba S, Suzuki E, Nishimatsu H, et al. Renoprotective effect of erythropoietin in ischemia/reperfusion injury: possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol 2012, 19(3):248-255. 10.1111/j.1442-2042.2011.02920.x, 22126194.
9. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004, 101(41):14907-14912. 10.1073/pnas.0406491101, 522054, 15456912.
10. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264(5):405-432. 10.1111/j.1365-2796.2008.02024.x, 19017170.
11. Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant 2010, 10(7):1695-1700. 10.1111/j.1600-6143.2010.03142.x, 20642691.
12. Hafer C, Becker T, Kielstein JT, et al. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int 2012, 81(3):314-320. 10.1038/ki.2011.349, 22012130.
13. Aydin Z, Mallat MJ, Schaapherder AF, et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012, 12(7):1793-1800. 10.1111/j.1600-6143.2012.04019.x, 22429395.
14. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012, 7(9):1498-1506. 10.2215/CJN.01360212, 22745272.
15. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008, 105(31):10925-10930. 10.1073/pnas.0805594105, 2504825, 18676614.
16. Patel NS, Kerr-Peterson HL, Brines M, et al. The delayed administration of pHBSP, a novel non-erythropoietic analogue of erythropoietin, attenuates acute kidney injury. Mol Med 2012, 18(1):719-727. 3388125, 22415011.
17. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995, 41(6 Pt 1):892-896.
18. Cassis P, Azzollini N, Solini S, et al. Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. Transplantation 2011, 92(3):271-279. 10.1097/TP.0b013e3182241106, 21705971.
19. Breggia AC, Wojchowski DM, Himmelfarb J. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol 2008, 295(6):F1689-F1695. 10.1152/ajprenal.90333.2008, 2753302, 18815218.
20. Ahmet I, Tae HJ, Juhaszova M, et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011, 17(3-4):194-200. 3060982, 21170473.
21. Ueba H, Brines M, Yamin M, et al. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci USA 2010, 107(32):14357-14362. 10.1073/pnas.1003019107, 2922582, 20660739.
22. Patel NS, Nandra KK, Brines M, et al. A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med 2011, 17(9-10):883-892. 3188881, 21607291.
23. Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE. Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens 2008, 26(1):110-116. 10.1097/HJH.0b013e3282f1a93e, 18090547.